XTALPI (02228) soared 9.87% intraday, propelled by the company's formal launch of its XtalPi Science platform and the formation of a Scientific Intelligence Open Ecosystem Alliance with 26 partner institutions.
The platform release has shifted market expectations, prompting a valuation re-rating from a traditional CRO service provider to an AI platform company. Under the alliance framework, members gain access to platform resources, automation lab capabilities, and co-development opportunities. The approaching earnings window, with the board set to review interim results on August 19, also drew incremental capital attention.
The broader AI drug discovery sector rallied in tandem, with peers like INSILICO and GENSCRIPT BIO posting notable gains, signaling strong capital resonance across the space.
Comments